SS Innovations International, Inc. (SSII) Form 8-K — Aug 13, 2026
SS Innovations International (Nasdaq: SSII) reported record second-quarter 2026 revenue of $13.9 million, up 39.4% year over year, driven by SSi Mantra surgical robotic system sales, and filed its Form 10-Q for the quarter ended June 30, 2026 the same day. Profitability moved the other way: gross margin fell to 50.9% from 59.1% a year ago, the company swung to a $2.3 million operating loss, and Q2 net loss widened to $2.7 million ($0.01 per diluted share) from $0.3 million. Adoption metrics stayed strong, with 30 systems installed in the quarter (up 30.4% YoY), a cumulative base of 224 systems across twelve countries, and 12,272 cumulative surgeries including 175 telesurgeries.
Key figures
- Revenue
- 13939709
- Guidance
- FDA expected to complete its 510(k) premarket notification review of the SSi Mantra by the end of Q1 2027; EU CE marking certification targeted by the end of 2026.
- Revenue Yoy
- 39.4%
- Total Assets
- 96982013
- Cash Position
- 13647430
- Shares Outstanding
- 200169035
- Countries
- 12
- Telesurgeries
- 175
- H1 revenue yoy
- 65.6%
- Long term debt
- 0
- H1 2025 revenue
- 15120915
- H1 2026 revenue
- 25041075
- H1 gross profit
- 12428171
- Q2 2025 revenue
- 10000305
- Q2 gross margin
- 50.9%
- Q2 gross profit
- 7100950
- Q2 system sales
- 12361986
- H1 installations
- 56
- Q2 installations
- 30
- Total liabilities
- 43580790
- Cardiac procedures
- 637
- Pediatric surgeries
- 222
- Stockholders equity
- 53401223
- Cumulative surgeries
- 12272
- H1 pipe proceeds net
- 18446498
- Q2 2025 gross margin
- 59.1%
- Bank overdraft facility
- 14634960
- Cumulative installed base
- 224
Price after filing
Close on the filing date to close N calendar days later (from $3.69). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.